Fate Therapeutics Inc
FATE
Get informed when a big investor buys or sells
+ FollowMarket Cap$326.37M
Close$
$-0.51
120.2% downside
Current Fair Value
120.2% downsideOvervalued by 120.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $326.37 Million |
|---|---|
| Enterprise Value | $364.16 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.15 |
| Beta | 2.52 |
| Outstanding Shares | 120,030,638 |
Return
| Return on Equity | -72.29% |
|---|---|
| Return on Assets | -45.59% |
| Return on Invested Capital | -55.74% |
Valuation & Multiples
| P/E Ratio | -2.57 |
|---|---|
| PEG | 15.08 |
| Price to Sales | - |
| Price to Book Ratio | 2.52 |
| Enterprise Value to Revenue | 57.66 |
| Enterprise Value to EBIT | -2.57 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.43 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$1.37 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$1.34 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 73.41% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10.68%▼ 51.04% |
|---|---|
| Total Invested | $34.63M▼ 61.03% |
| Investors Holding | 53▼ 108.00% |
ESG Score
No data
About Fate Therapeutics Inc
CEO: William Rastetter